These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38360041)

  • 1. Correction: RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38360041
    [No Abstract]   [Full Text] [Related]  

  • 2. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.
    Meng Y; Liu H; Zhu H; Zhang W; Sun D; Han X; Liu Y; Luo G
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.
    Wei F; Wang H; Chen X; Li C; Huang Q
    Cancer Biol Ther; 2014 Oct; 15(10):1358-66. PubMed ID: 25019940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment.
    Liu G; Hu Q; Peng S; Ning H; Mai J; Chen X; Tao M; Liu Q; Huang H; Jiang Y; Ding Y; Zhang X; Gu J; Xie Z
    Cancer Lett; 2024 Jan; 581():216485. PubMed ID: 38008394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
    Wang S; Li Y; Xu C; Dong J; Wei J
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models.
    Liu W; Wang X; Feng X; Yu J; Liu X; Jia X; Zhang H; Wu H; Wang C; Wu J; Yu B; Yu X
    Cancer Lett; 2022 Jun; 535():215661. PubMed ID: 35325845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
    Choi IK; Li Y; Oh E; Kim J; Yun CO
    PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells.
    Liang Z; Chen W; Guo Y; Ren Y; Tian Y; Cai W; Bao Y; Liu Q; Ding P; Li Y
    Front Immunol; 2023; 14():1133883. PubMed ID: 37266424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune response in liver cancer.
    Qiang L; Huili Z; Leilei Z; Xiaoyan W; Hui W; Biao H; Yigang W; Fang H; Yiqiang W
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18201-18213. PubMed ID: 38078962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
    Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
    Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
    Ahn HM; Hong J; Yun CO
    Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
    Zhang J; Guo Y; Fang H; Guo X; Zhao L
    Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma.
    Zhang Q; Zhang J; Tian Y; Wang J; Jin G; Liu F
    Virology; 2023 Oct; 587():109885. PubMed ID: 37738842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
    Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
    J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.